Victhom completes enrollment for its Neurostep(R) clinical study



    QUEBEC, June 9 /CNW Telbec/ - Victhom Human Bionics Inc., ("Victhom")
(TSX: VHB), announced today that it had completed the enrollment of the
ongoing human clinical study of its Neurostep(R) System at the end of March
2009. According to the Company, preliminary data shows promising results for
the primary endpoints of the study, which are the safety and technical
performance of the Neurostep(R) System. The Company expects the formal results
of the clinical study to be available by the end of 2009.
    Mr. Nader Kameli, Chief Operating Officer of the Neurobionix division,
said: "We are pleased with the preliminary results coming out of the clinical
study and with the feedback we have received from principal investigators and
patients involved in this study. This clinical study will be the platform from
which we will design and deploy the next North American study to be conducted
in the United States and in Canada. Combined with the CE Mark approval
received earlier this year, results from this study will allow Neurostream
Technologies, our recently announced partnership with Otto Bock HealthCare
GmbH, to increase market development activities in preparation for the
European launch of the Neurostep(R) System."

    About the Neurostep(R) System Clinical Study

    The ongoing human clinical study on the Neurostep(R) System has two major
objectives. The first is to evaluate the safety as well as the sensing and
stimulation mechanisms of the system, and the second is to evaluate the
efficacy of the Neurostep(R) in providing clinically measurable benefits, such
as helping patients to walk faster and over longer distances.
    The Neurostep(R) System, a fully implantable investigational
neuromodulation product designed to treat gait disorders (e.g., foot drop), is
the first closed-loop system (CLS) product aimed at using the patients' own
nervous system as the source for detection of intention to move and control
their leg. Contrary to other systems that use surrogates such as external
sensors, the Neurostep(R) detects intrinsic muscle activities and surface
sensation events from the nerve signals delivered to the spine and brain. This
information is then used as the trigger for intervention through
neurostimulation, as needed, to complete function.

    Management Proxy Circular

    Victhom has released an amended version of its Management Proxy Circular
in order to comply with the new requirements of the Autorité des machés
financiers as specified in Appendix 51-102F6 concerning Executive
Compensation. For this purpose, additional information regarding stock-option
based compensation, more precisely, the fair value of options granted during
2008 as well as details on unexercised options at the end of 2008 and
directors' compensation were added. The amended circular is available on SEDAR
(www.sedar.com).

    About Victhom

    Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.

    FORWARD-LOOKING STATEMENTS

    Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
statements.




For further information:

For further information: Normand Rivard, Acting President & CFO, Victhom
Human Bionics Inc., (418) 872-5665, Fax: (418) 872-6926,
normand.rivard@victhom.com, www.victhom.com; Source: Victhom Human Bionics
Inc.

Organization Profile

Victhom Human Bionics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890